Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intraoperative Fluid Responsiveness After Mini Fluid Challenge. (REFILL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03810118
Recruitment Status : Not yet recruiting
First Posted : January 18, 2019
Last Update Posted : March 7, 2019
Sponsor:
Information provided by (Responsible Party):
Antonio Messina, Humanitas Clinical and Research Center

Brief Summary:

It is unclear if the rate of administration of the fluid challenge could affect the rate of fluid responsiveness.

The role of this small-dose (the so called mini-FC) has been recently tested to assess if the infusion of a small amount of fluids (100 ml in 1 minute) could predict the final effect of the residual aliquot (i.e., 250 ml of FC test subdivided as follows: 100 ml in 1 minute and 150 ml in 9 minutes). Both the sudden increase in the stroke volume and the reduction of PPV and SVV after a bolus of 100 ml of crystalloids administered in 1 minute showed high sensitivity and specificity in predicting the final outcome of the FC.

The primary aim of the present study is assess whether the does the rate of infusion of fluid challenge affect fluid responsiveness in neurosurgical supine patients.

The secondary aim is to assess the reliability of the changes in SV, PPV and SVV after a mini-FC test in predicting the final fluid responsiveness.


Condition or disease Intervention/treatment Phase
Neurosurgery Cardiovascular System Anesthesia, General Diagnostic Test: fluid challenge Not Applicable

  Hide Detailed Description

Detailed Description:

Dedicated algorithms and protocols of anaesthetic care regarding fluid therapy are key factors to prevent perioperative hypovolaemia and/or hypervolemia, which are known to increase morbidity and length of hospital stay.

Fluid therapy is commonly used in critically ill and surgical patients to restore hemodynamics. The aim of volume expansion is to increase cardiac index and oxygen delivery and to improve tissue oxygenation. However, this occurs only in a situation of preload dependency (i.e. when the ventricle operates on the steep part of the Frank-Starling's curve). Moreover, giving fluids to a non-volume-responsive patient (preload independency) can result in detrimental pulmonary and interstitial oedema. Fluid responsiveness (i.e., increase in stroke volume, SV, after fluid challenge, FC, administration) can be detected in 35-50% of both critically ill and surgical patients. The FC consists in assessing the hemodynamic effects of giving a small amount of fluid in a short period of time. The FC allows restoring fluid depletion when indicated, while minimizing the risk of overloading, which makes it the gold standard for assessing fluid depletion in patients undergoing surgery.

Then, FC administration should be based on predictors of fluid responsiveness. Static indexes, such as the central venous pressure, do not seem appropriate, whereas dynamic indexes, such as pulse pressure variation (PPV) and stroke volume variation (SVV), reliably predict the effect of FC administration during controlled mechanical ventilation only in case of a tidal volume (VT) of at least 8 mL/kg, which unfortunately are rarely found in both critically ill and surgical patients.

To overcome this VT-related limitation of PPV and SVV, the prediction of fluid responsiveness can be also achieved by applying functional hemodynamic tests aiming at increasing venous return and enhancing right ventricle preload dependence.

For example, when a FC is performed using a rapid infusion rate and a relatively "small" dose, its effect is sufficient to test whether the patient is on the ascending part of the cardiac function curve, hence showing an increase in cardiac output (CO).

The role of this small-dose (the so called mini-FC) has been recently tested to assess if the infusion of a small amount of fluids (100 ml in 1 minute) could predict the final effect of the residual aliquot (i.e., 250 ml of FC test subdivided as follows: 100 ml in 1 minute and 150 ml in 9 minutes). Both the sudden increase in the stroke volume and the reduction of PPV and SVV after a bolus of 100 ml of crystalloids administered in 1 minute showed high sensitivity and specificity in predicting the final outcome of the FC. However, the mini-FC has been tested, insofar, only in small-sized studies, needing further investigations to be confirmed.

Moreover, the response to the FC is transitory, and as such also its clinical effect. The study of Aya et al. pointed out that the effect of the FC is dissipated in about 10 minutes in both responders and non-responders and that a dose of 4 ml/kg of crystalloids is the lowest one to evocate a significant hemodynamic effect. It remains unclear, however, what the best approach to FC administration should be and, in fact, wide variability exists at this regard among studies performed both in the perioperative setting and in the intensive care unit (ICU). In fact, the rate of fluid administration is not fixed. A recent systematic review showed a significant heterogeneity. In a subgroup of 35 studies three (8.6%) reported an infusion rate of 1 ml/kg/min. In another group of 32 studies, the FC was administered in 30 minutes in 7 (21.8%) studies, in 20 minutes in 2 (6.2%) studies, in 13 minutes in 1 (3.1%) study, in 10 minutes in 15 studies (46.8%), in 5 minutes in 4 (12.5%) studies, in 3 minutes in 1 (3.1%) study, and in 2 minutes in 2 (6.2%) studies. The median (IQR) time of infusion was 10 (5-20) minutes.

After the indication of Aya et al., 4 ml/kg of crystalloids is the standard dose for the FC in our center. However, it is unclear if the rate of administration could affect the rate of fluid responsiveness. We, therefore, will perform a study to address this issue in a sample of neurosurgical patients.

The primary aim of the present study is assess whether the does the rate of infusion of fluid challenge affect fluid responsiveness in neurosurgical patients.

The secondary aim is to assess the reliability of the changes in SV, PPV and SVV after a mini-FC test in predicting the final fluid responsiveness.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 98 participants
Intervention Model: Single Group Assignment
Intervention Model Description: A single group of patient will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Intraoperative Fluid Responsiveness After Mini Fluid Challenge: an Open-label, Multicentric, Randomized Clinical Trial.
Estimated Study Start Date : March 1, 2019
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019

Arm Intervention/treatment
Experimental: Treatment
All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
Diagnostic Test: fluid challenge
A first aliquot of a of 100ml mini FC infused over 1 minute, followed by a the rest aliquot of a 4 ml/kg fluid challenge infused over in either 10 or 20 minutes




Primary Outcome Measures :
  1. Percentage of fluid responders [ Time Frame: 10 or 20 minutes from the start ]
    Percentage of patients showing an increase in the stroke volume above the predefined threshold of fluid responsiveness after the infusion of the fluid challenge (>10%).


Secondary Outcome Measures :
  1. Pulse pressure Variation (PPV) changes between baseline and after mini-FC test [ Time Frame: 1 minute ]
    To assess the sensitivity and specificity of PPV changes after the mini-FC test (100 ml administered in 1 minute) in predicting fluid responsiveness. This change will be assessed by a continuous measurement of PPV obtained by means of MOSTCARE(TM) system.

  2. Stroke volume changes between baseline and after mini-FC test [ Time Frame: 1 minute ]
    To assess the sensitivity and specificity of the stroke volume changes after the mini-FC test (100 ml administered in 1 minute) in predicting fluid responsiveness. This change will be assessed by a continuous measurement of stroke volume obtained by means of MOSTCARE(TM) system.

  3. Stroke volume variation (SVV) changes between baseline and after mini-FC test [ Time Frame: 1 minute ]
    o assess the sensitivity and specificity of PPV changes after the mini-FC test (100 ml administered in 1 minute) in predicting fluid responsiveness. This change will be assessed by a continuous measurement of SVV obtained by means of MOSTCARE(TM) system.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients aged ≥ 18 years;
  2. Scheduled for elective supine neurosurgery and requiring invasive arterial monitoring;
  3. Glasgow coma scale 15 at recruitment

Exclusion Criteria:

  1. Any recurrent cardiac arrhythmias;
  2. Reduced left (ejection fraction <30%) or right (systolic peak velocity of tricuspid annular motion <0.17 m/s) ventricular systolic function;
  3. Intra-operative use of vasopressors or inotropes before FC administration or between the first and the second bolus of fluids.
  4. Chronic use beta-blocking agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03810118


Locations
Layout table for location information
Italy
Humanitas Research Hospital Not yet recruiting
Rozzano, Milano, Italy, 20089
Contact: Antonio Messina, MD    +390282241    antonio.messina@humanitas.it   
Contact: Antonio Messina, MD    +3902822414131    mess81rc@gmail.com   
Sponsors and Collaborators
Humanitas Clinical and Research Center

Publications of Results:
Layout table for additonal information
Responsible Party: Antonio Messina, ICU senior consultant, Humanitas Clinical and Research Center
ClinicalTrials.gov Identifier: NCT03810118     History of Changes
Other Study ID Numbers: REFILL
First Posted: January 18, 2019    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No